Clinicopathological and functional significance of XRCC1 expression in ovarian cancer

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2778-2786

  Abdel Fatah, Tarek ^a   Sultana, Rebeka ^a   Abbotts, Rachel ^a   Hawkes, Claire ^a   Seedhouse, Claire ^b   Chan, Stephen ^a   Madhusudan, Srinivasan ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

DNA repair; ovarian cancer; platinum therapy; predictive; prognostic biomarker; XRCC1

Indexed keywords

CISPLATIN; DOUBLE STRANDED DNA; XRCC1 PROTEIN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CHO CELL; CLINICAL FEATURE; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA STRAND BREAKAGE; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CRICETINAE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; RNA INTERFERENCE; TREATMENT OUTCOME; TUMOR STEM CELL ASSAY;

EID: 84876126391     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27980     Document Type: Article

References (29)

1. Han LY, Kipps E, Kaye SB,. Current treatment and clinical trials in ovarian cancer. Expert Opin Investig Drugs 2010; 19: 521-34.
2. Yap TA, Carden CP, Kaye SB,. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009; 9: 167-81.
3. Berkenblit A, Cannistra SA,. Advances in the management of epithelial ovarian cancer. J Reprod Med 2005; 50: 426-38.
4. Friedberg EC,. DNA damage and repair. Nature 2003; 421: 436-40.
5. Tan DS, Ang JE, Kaye SB,. Ovarian cancer: can we reverse drug resistance? Adv Exp Med Biol 2008; 622: 153-67.
6. Siddik ZH,. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 7265-79.
7. Rabik CA, Dolan ME,. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
8. Nouspikel T,. DNA repair in mammalian cells: nucleotide excision repair: variations on versatility. Cell Mol Life Sci 2009; 66: 994-1009.
9. Shuck SC, Short EA, Turchi JJ,. Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology. Cell Res 2008; 18: 64-72.
10. Svilar D, Goellner EM, Almeida KH, et al. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal 2011; 14: 2491-507.
11. Robertson AB, Klungland A, Rognes T, et al. DNA repair in mammalian cells: base excision repair: the long and short of it. Cell Mol Life Sci 2009; 66: 981-93.
12. Ladiges WC,. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene 2006; 25: 1612-9.
13. Horton JK, Watson M, Stefanick DF, et al. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res 2008; 18: 48-63.
14. Caldecott KW,. XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003; 2: 955-69.
15. Moser J, Kool H, Giakzidis I, et al. Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 2007; 27: 311-23.
16. Wilson DM, III, Kim D, Berquist BR, et al. Variation in base excision repair capacity. Mutat Res 2011; 711: 100-12.
17. Corso G, Marrelli D, Pedrazzani C, et al. Gastric cardia carcinoma is associated with the promoter -77T>C gene polymorphism of X-ray cross-complementing group 1 (XRCC1). J Gastrointest Surg 2009; 13: 2233-8.
18. Gossage L, Madhusudan S,. Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy. Mol Diagn Ther 2007; 11: 361-80.
19. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-601.
20. Kim K, Kang SB, Chung HH, et al. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 2008; 111: 509-15.
21. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009; 65: 230-6.
22. Cheng CX, Xue M, Li K, et al. Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. Asian Pac J Cancer Prev 2012; 13: 2541-5.
23. Li K, Li W,. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Mol Cell Biochem 2013; 372: 27-33.
24. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005; 97: 1180-4.
25. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
26. Fan J, Wilson PF, Wong HK, et al. XRCC1 down-regulation in human cells leads to DNA-damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells. Environ Mol Mutagen 2007; 48: 491-500.
27. Sultana R, McNeill DR, Abbotts R, et al. Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. Int J Cancer 2012; 131: 2433-44.
28. Zhang R, Niu Y, Zhou Y,. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol Lett 2010; 192: 108-14.
29. Ang MK, Patel MR, Yin XY, et al. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2011; 17: 6542-52.